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To the Editor: As a case of The Renal Consult, Sperati et al.1
presented a 46-year-old man with renal infarctions and renal
artery stenoses (RASs). Although their clinical diagnosis was
bilateral intimal fibromuscular dysplasia (FMD) complicated
by dissection, several distinctions of the case would indicate
other causative abnormalities for the RASs, such as athero-
sclerosis and arteritis.
Although the renal arteriographic image is characteristic
of intimal FMD, either atherosclerosis or arteritis can present
arteriographic images similar to those seen in intimal FMD.2
A middle-aged man could have atherosclerosis, especially if
he were a smoker. The intravascular ultrasound image, a
crescent-shaped hypoechoic lesion with an echogenic layer on
its vascular surface, would indicate lipid-laden atherosclerosis
with a thin fibrous cap.3 Several echogenic clefts inside the
hypoechoic lesion would be fibrous or calcified components
of atherosclerosis rather than dissection flaps. It would be
unlikely that dissection flaps had been embedded in a thick
thrombus covered by a fibrous cap. Furthermore, the
episodes of fever and spontaneous improvement in vascular
lesions while taking prednisone might indicate superimposed
inflammatory changes; these episodes are rarely noted in
FMD.2
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Dr Tanemoto suggests that the intravascular ultrasound
image may be more consistent with a lipid-laden atheroma,
indicating that the patient may have actually had athero-
sclerotic renal artery stenosis (RAS) rather than intimal
fibromuscular dysplasia (FMD). In addition, Dr Tanemoto
proposes that the improvement in vascular lesions and
fever after the administration of prednisone might suggest
an inflammatory etiology to the vascular lesions.1 We agree
that intimal FMD can be difficult to distinguish angio-
graphically from atherosclerotic disease.2 The features of
this case, however, strongly supports FMD rather than
RAS. The patient had multiple areas of stenosis in the
distal, smaller renal vessels—angiographic findings
typical for FMD and unusual in RAS.3 The intravascular
ultrasound image shows low-intensity echoes without
significant calcification—findings more typical of a dissec-
tion than atherosclerotic RAS. Moreover, the relatively
young age of this patient who did not smoke, and the
absence of peripheral arterial disease, places him at low
risk for RAS. The low-grade fevers before admission are
consistent with renal infarction, and the absence of
significant markers of infla mmation is consistent with a
diagnosis of FMD. Importantly, his clinical improvement
without ongoing immunosuppressive therapy essentially
excludes a diagnosis of polyarteritis nodosa.
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To the Editor: In their elegant review, Cachofeiro et al.1
related cardiovascular risk to oxidative stress, inflammation,
and atherogenesis and report the results of treatment with
statins on the prevention of cardiovascular disease (CVD) in
the general population and in chronic kidney disease
patients. Peripheral blood mononuclear cell (PBMC)
5-lipoxygenase (5-Lox) activity is involved in low-density
lipoprotein oxidation during the early phases of athero-
genesis. 5-Lox activity and expression are upregulated in
PBMC of uremic patients under maintenance hemodialysis
(MHD).2 The subsequent increase in membrane lipid
peroxidation, reactive oxygen species production, and low-
density lipoprotein oxidation seems to contribute to the
susceptibility of uremic patients to atherosclerosis and CVD.
Antioxidant and anti-inflammatory ‘pleiotropic’ actions of
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statins have been widely investigated, and their use is usually
recommended in the secondary prevention of acute coronary
syndrome (ACS). To investigate the use of statins for the
primary prevention of ACS, between April 2004 and February
2005 we enrolled a total of 31 end-stage renal disease patients
on MHD, with neither history nor clinical and instrumental
signs of earlier major adverse cardiac events (MACEs). We
started each patient on atorvastatin (10 mg) daily regardless
of serum low-density lipoprotein cholesterol associated with
conventional pharmacologic control of blood pressure, serum
glucose, and calcium–phosphate balance. During a 4-year
follow-up overall 3-year actuarial survival was 67%,3
compared with a 20–40% 5-year survival reported earlier.4
Cardiovascular mortality was 12.9%, (4 patients). ‘MACE’
free’ (lethal and non-lethal) 3-year actuarial survival was
53%. Treatment with statins may be considered in the
primary prevention of MACEs in hemodialysis patients.
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Considering the clinical benefits of statins for primary
and secondary cardiovascular event prevention in normal
renal function patients, one can assume a similar benefit
for patients with chronic kidney disease. Accordingly,
Manca-di-Villahermosa’s letter1 reports that a small group
of end-stage renal disease patients receiving atorvastatin
show low cardiovascular mortality after 3 years of follow-
up. However, in the 4-D study—the only randomized
placebo-controlled statin trial done to date, which
included 1255 patients with type 2 diabetes undergoing
hemodialysis—atorvastatin administration was not
associated with cardiovascular mortality reduction, which
accounts for half the deaths in such patients.2 Moreover,
this occurs independently of the presence or absence of
high c-reactive protein levels that are associated with
cardiovascular event risk.3 Reasons for this discrepancy are
not evident, as statins exert anti-inflammatory, antiox-
idant, and lipid-lowering effects as effective as those
observed in normal renal function participants. End-stage
renal disease patients are at high risk for cardiovascular
complications, in whom cardiovascular disease is con-
sidered complex and aggravated by coexisting factors,
including malnutrition, accelerated atherosclerosis, left
ventricular hypertrophy, cardiac fibrosis, and sympathetic
overactivity. In the 4-D study, most of cardiovascular
deaths were caused by sudden death and not by coronary
heart disease.2 Data for two ongoing large trials (AURORA
and SHARP) would help put into perspective statin’s
beneficial effect in chronic kidney disease with respect to
cardiovascular mortality. Apart from this, it has been
reported that statin use is associated with sepsis incidence
reduction—a major cause of morbimortality in chronic
kidney disease.4 This protective benefit could contribute to
total mortality reduction in peritoneal dialysis and
hemodialysis patients using statins reported by some
observational studies (e.g., DOPPS).5
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On vascular calcification
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To the Editor: Phosphonoformic acid (PFA) is a non-
hydrolyzeable inorganic pyrophosphate analog, and it
has been used as an experimental inhibitor of renal and
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